
Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.
HypertensionPrimary objective:To demonstrate the no-inferiority in efficacy of treatment with Torsemide-PR in relation to Torsemide-IR in patients with mild and/or moderate hypertension. Secondary objectives: To evaluate the safety and tolerability of Torsemide-PR.

Irbesartan in Chinese Hypertensive Diabetics With Microalbuminuria
HypertensionPrimary objective: To determine if irbesartan 300mg is better than 150mg in protecting the kidneys in hypertensive patients with diabetes and microalbuminuria. Secondary objectives: To determine how well irbesartan 300mg is tolerated versus 150mg To determine the percentage of patients reaching the blood pressure target of 130/80 mmHg

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension
HypertensionThis is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more antihypertensive drugs, including a diuretic.

Diva - The Effects Of 12 Weeks Of Treatment With High Dose Valsartan (320 Mg) To Amlodipine On Endothelial...
HypertensionMetabolic SyndromeA STUDY ON WHETHER AN ANTIHYPERTENSIVE MEDICATION PREVENTS DAMAGE TO WALLS OF VEINS IN FEMALE PATIENTS WITH THE METABOLIC SYNDROME (OVERWEIGHT AND OTHER DISORDERS).

I PREVENT - Irbesartan In Hypertensive Diabetic Patients
HypertensionTo evaluate Blood Pressure (BP) reduction to the targeted values (Systolic BP ≤ 130 mmHg and Diastolic BP ≤ 80 mmHg) in hypertensive type 2 diabetic patients. To evaluate the benefit of Irbesartan in the reduction of microalbuminuria from baseline (if any at the inclusion visit) in this population. To demonstrate the safety of Irbesartan in this population.

Ramipril and Hydrochlorothiazide Alone and in Combination for the Treatment of Essential Hypertension...
HypertensionBlood Pressure1 moreThe purpose of this study is to determine if there is greater blood pressure reduction using ramipril or hydrochlorothiazide alone or ramipril and hydrochlorothiazide together.

A Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant...
HypertensionThis is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more blood pressure lowering drugs, including a diuretic.

Doxazosin Effects on ABPM in Hypertensive Patients With Diabetic Nephropathy
Diabetes MellitusEssential Hypertension1 moreFew studies have reported the effect of alpha1-adrenergic antagonists on 24-h blood pressure and regulation of sympathetic nervous activity in hypertensive patients with diabetic nephropathy. Using ambulatory blood pressure monitoring devices equipped with spectral analysis of heart rate variability, we assess the effects of doxazosin on blood pressure in diabetic nephropathy patients and compare the results with those in patients with essential hypertension, patients with diabetes mellitus and patients with chronic nephropathy.

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension...
HypertensionThis study will assess the efficacy and safety of valsartan/hydrochlorothiazide combination therapy in patients with hypertension not controlled with hydrochlorothiazide monotherapy.

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM...
HypertensionThe primary objective of this study is to demonstrate that telmisartan 80 mg (MICARDIS®) is at least as effective and possibly superior to ramipril 5mg and 10mg in lowering mean ambulatory diastolic blood pressure (DBP) and systolic blood pressure (SBP) during the last 6 hours of the 24-hour dosing interval in mild-to-moderate hypertensive patients at the end of an 8 and 14-week treatment period, respectively.